MOUNTAIN VIEW, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that Fred Schwarzer , Chief Executive Officer,

MOUNTAIN VIEW, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced its financial results for the third quarter ended

MOUNTAIN VIEW, Calif. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that the first patient has been dosed in its Phase 1 clinical

MOUNTAIN VIEW, Calif. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the closing of its initial public offering of 12,578,125 shares of its common stock at a price to the public of $16.00 per share, which includes the exercise in full by the underwriters

MOUNTAIN VIEW, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the pricing of its initial public offering of 10,937,500 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The Nasdaq

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of engineered IgM antibodies for therapeutic use, today announced the closing of its $102 million Series C financing. New investors included Redmile Group, Janus Henderson

Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership IGM Biosciences, Inc.  (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of M. Kathleen

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience  IGM Biosciences, Inc.  (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Misbah Tahir to the newly